

Special Issue

Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects

Message from the Guest Editors

Vaccination into the dermal compartment is an attractive delivery route due to the rich populations of immune cells in this tissue space. It is possible to use less vaccine and induce an effective immune response that is similar or even enhanced compared to intramuscular delivery using larger doses. Despite the benefits of intradermal vaccination, challenges remain. This Special Issue aims to address the various benefits and challenges when employing intradermal vaccine delivery in order to inform the development of vaccination regimens and health and policy decisions to implement vaccination campaigns. In this Special Issue, original research may include (but are not limited to) the:

- Intradermal vaccination regimens, injection techniques, physical delivery methods (needle and syringe, electroporation, jet injection, microneedles, etc.), comparison to other routes of injection
- Development of new intradermal vaccination technologies
- Public health and policy issues, including mass vaccination campaign planning and deployment, and costs analyses of different intradermal vaccination techniques

Guest Editors

Dr. Carmen Ledesma-Feliciano

Scientific Affairs Manager, PharmaJet, 400 Corporate Circle, Unit N, Golden, CO 80401, USA

Dr. Erin Spiegel

Vice President, Regulatory and Clinical Departments, PharmaJet, 400 Corporate Circle, Unit N, Golden, CO 80401, USA

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/159828

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).